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Aim: This study set out to describe the initial clinical findings, morbidity, mortality and aetiology of
infant cardiomyopathy focusing on potential risk factors for an adverse outcome.
Methods: We retrospectively analysed clinical and laboratory findings of all patients diagnosed at our
institution from 1995 to 2004 with cardiomyopathy within their first year of life.
Results: Of the 35 patients, cardiomyopathy was classified as dilated in 18, hypertrophic in 14 and
unclassified in 3. The aetiologies were genetic syndromes (8), metabolic diseases (5), familial
isolated cardiomyopathy (3) and myopathy (1). During a median follow-up of 1.5 years (range 0–
9 years), 13 patients died from progressive heart failure and two underwent heart transplants.
Estimated survival and freedom from transplant was 69, 66, 58 and 50% after 0.5, 1, 2 and 6 years,
respectively. Patients with severe heart failure symptoms within the first month of life had significantly
worse outcomes than patients without heart failure symptoms.
Conclusion: High morbidity and poor prognosis result through progressive heart failure. Aetiology and clinical
course are especially heterogeneous in infants. The most commonly identified aetiologies are genetic syndromes
and metabolic diseases. A multidisciplinary approach is recommended for defining the aetiology and developing
individual treatment strategies.
INTRODUCTION
Cardiomyopathy is a disease of the heart muscle charac-
terized by the presence of systolic or diastolic dysfunction
or abnormal myocardial structure. The annual incidence is
around 8 per 100000 within the first year of life (1). Car-
diomyopathies are subdivided into hypertrophic, dilated, re-
strictive, arrhythmogenic right ventricular and unclassified
cardiomyopathies (2).
In infants, cardiomyopathy often forms part of a systemic
disease involving multiple organ systems, such as genetic
syndromes, metabolic diseases and neuromuscular disorders
(3–5).
Progression from the hypertrophic to the dilated form of
cardiomyopathy is possible in one and the same patient.
There are only a few patients in whom a causal therapy can
be initiated. There is little published data about aetiology
and clinical courses of cardiomyopathy in infants. Coun-
selling and risk assessment may be difficult due to a lack
of knowledge on the clinical course and prognostic factors.
This study set out to identify predictors for an adverse out-
come by critically assessing the clinical findings, morbidity,
mortality and aetiology of all infants with cardiomyopathy,
seen at our institution over the last 10 years.
Abbreviations
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomy-
opathy; UCM, unclassified cardiomyopathy.
PATIENTS AND METHODS
This study is a retrospective analysis in a single tertiary care
centre. We included all consecutive infants and neonates
with cardiomyopathy diagnosed within the first year of life
and born in the years from 1995 to 2004. Patients with
secondary cardiomyopathy due to longstanding tachycar-
dia, cardiac surgery or elevated ventricular pressures were
excluded from the study.
Patients were divided into five groups: dilated, hyper-
trophic, restrictive, right ventricular arrhythmogenic and
unclassified cardiomyopathies (such as non-compaction) in
accordance with the WHO classification (2). Dilated car-
diomyopathy (DCM) is characterized by dilatation and/or
impaired contraction of the left ventricle or both ventricles
(2). A left ventricular end-diastolic dimension of more than
2 standard deviations above the mean normal values (6)
was considered as dilated. An ejection fraction of 55% or
less or a shortening fraction of 28% or less was regarded
as impaired contraction (7). Hypertrophic cardiomyopathy
(HCM) was defined by a septal or posterior wall thickness
that was more than 2 standard deviations above the mean
normal thickness (6).
Patients were subdivided according to aetiology as fol-
lows: genetic syndromes, metabolic diseases, neuromuscu-
lar disease, familial isolated cardiomyopathy, inflammation
and unknown aetiology (8).
The genetic syndromes were subdivided into three groups.
(1) Classified syndrome: the patient shows dysmorphic find-
ings typical of a known syndrome, and genetic analysis
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Figure 1 Distribution of the patients over the 10 years of the study period.
confirmed the diagnosis. (2) Suspected known syndrome:
the patient shows dysmorphic findings typical for a known
syndrome, but genetic confirmation was either not feasible
(because the responsible gene is still unknown) or no muta-
tion in the gene known to cause the syndrome was detected.
(3) Suspected unknown syndrome: the patient shows multi-
ple dysmorphic findings but a recognizable syndrome could
not be classified.
Heart failure was defined as severe when catecholamines
and/ or intubation was required.
The study was approved by the local hospital ethical com-
mittee, and written informed consent was obtained for the
data collection.
For statistical analysis, we used SPSS 14.0 for Windows.
Patient groups were compared using the Mann–Whitney U-
test or crosstabs and chi-square test. p-value < 0.05 was
defined as significant. Survival was calculated with Kaplan–
Meier analysis. Echocardiographic values were compared
using the Z score.
RESULTS
Type of cardiomyopathy
Over the 10-year-period, 35 infants presented with car-
diomyopathy. Figure 1 shows the distribution of the cases
Table 1 Demographic data, outcome and symptoms of heart failure in 35 patients with cardiomyopathy
DCM HCM UCM ALL
Demographic data Number of patients 18 14 3 35
Percentage of all 51 40 9 100
Sex (F/M) 1.25 0.27 2.00 0.75
Age at diagnosis (days): median (range) 28 (0–304) 75 (0–332) 3 (0–148) 26 (0–332)
Outcome Death or transplant: N (%) 8 (44) 4 (29) 3 (100) 15 (43)
Age at death/transplant (days): median (range) 86 (2–1907) 94 (53–118) 31 (3–520) 83 (2–1907)
Symptoms of heart failure Severe heart failure: N (%) 8 (44.5) 3 (21) 3 (100) 14 (40)
Mild or moderate heart failure: N (%) 8 (44.5) 6 (43) 0 (0) 14 (40)
No heart failure: N (%) 2 (11) 5 (36) 0 (0) 7 (20)
DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; UCM = unclassified cardiomyopathy.
over the 10 years. DCM and HCM were the two leading
types of cardiomyopathy, while restrictive and right ven-
tricular arrhythmogenic cardiomyopathies were not repre-
sented (Table 1). Three infants were in the unclassified
cardiomyopathy (UCM) group: the first patient fulfilled the
criteria for non-compaction (9). Genetic analysis failed to
demonstrate a mutation characteristic for Barth syndrome.
The second patient showed a small left ventricle with a
spongy myocardium and moderately impaired ventricular
function. His right ventricle was mildly enlarged and its
function mildly impaired. The aetiology remained unknown,
and he died at the age of 1month. The third infant with UCM
suffered from long-chain 3-hydroxyacyl-CoA dehydroge-
nase (LCHAD) deficiency. His ventricular myocardium was
neither dilated nor hypertrophic but the left ventricular func-
tionwas severely impairedwith a shortening fraction of 17%.
He died at the age of 3 days
Aetiology
In 51% (n= 18) of the patients the aetiology of the cardiomy-
opathy remained unknown. The identified aetiologies (49%)
were all genetic (Fig. 2). Genetic syndromes and metabolic
diseases are themost frequent aetiologies (Table 2).
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Figure 2 Aetiology of 35 patients with cardiomyopathy; number of patients.
With DCM, the aetiology remains unknown more fre-
quently than for HCM (66% vs. 29%; p = 0.037, Table 2).
It was possible to assign patients with HCM to a genetic
syndrome more frequently.
Clinical presentation
Heart failure was the most frequent reason for the first con-
sultation in our cohort (Table 3). Heart failure, if present,
was severe in most of the patients and required intuba-
tion and/or catecholamines in 25/28 patients during sub-
sequent follow-up. The DCM group had a high heart failure
rate (16/18), while more than a third of the patients with
HCM (5/14) were without symptoms (p = 0.095). A total of
7/35 patients remained free of any heart failure symptoms
throughout the duration of the study.
A systolic murmur was present in 25/35 infants at the
time of diagnosis. No correlation was found between heart
auscultation and the severity, morphology or aetiology of
the cardiomyopathy.
Table 2 Diagnosis, cardiac morphology and age of death or transplant of 35 patients with cardiomyopathy
Aetiology of the cardiomyopathy DCM (N) HCM (N) UCM (N) Age at death/ transplant
Genetic Syndrome Classified Noonan 1 Alive
Trisomy 18 1 4 days
Suspected known∗ Noonan 2 Alive
Costello 1 3.9 months
Cantu` syndrome 1 Alive
Suspected unknown† Dysmorphy syndrome 2 2.7; 3.4 months
Metabolic disease Barth syndrome 1 2 days
LCHAD deficiency 1 3 days
ATP synthase deficiency 1 Alive
Defects in complex I and IV of respiratory chain 1 Alive
Unclassified metabolic disease 1 4.3 months
Familial isolated 3 1.3; 62 months; alive
Myopathy Steinert’s dystrophia myotonica 1 1.7 months
Unknown 12 4 2
Total 18 14 3
∗Patient shows dysmorphic findings typical for a known syndrome, but genetic confirmation was either not feasible (because the responsible gene is still unknown)
or no mutation in the gene known to cause the syndrome was detected.
†Patient shows multiple dysmorphic findings but a recognizable syndrome could not be classified.
ATP = adenosine triphosphate; DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; LCHAD = long-chain 3-hydroxyacyl-CoA dehydrogenase
deficiency; UCM = unclassified cardiomyopathy.
Dysmorphic features were present in 16/35 infants. In 13
of these patients, a confirmed or possible genetic aetiology
was found (Table 2).
The ECG was normal in only four patients at first presen-
tation and in one at the end of follow-up. The most common
pathological finding was an unspecific ventricular repolar-
ization abnormality (20/33). The voltage criteria for ventric-
ular hypertrophy were fulfilled in 15 patients (DCM: 6/16,
HCM: 8/11, UCM: 1/3).
The echocardiography at presentation of infants with
DCM showed a median ejection fraction of 35% (7–57%)
and a median shortening fraction of 15% (6–38%). There is
a trend towards a lower initial shortening fraction in non-
survivors compared with survivors having DCM (15 vs. 20%;
p = 0.48). The size of the left ventricle reached its maximum
in most of the patients with DCM within the first year after
diagnosis (Fig. 3). In HCM, the median Z score of posterior
wall thickness was 3.6 at the beginning (−0.4 to 7.5) and 3.5
(0 to 10.5) at the end of the follow-up. Systolic function, as
measured by shortening fraction and ejection fraction, was
within the normal range in all patients with HCM; 6/14 pa-
tients with HCM had an outflow tract obstruction (5 left and
1 both outflow tracts).
Outcome
During a median follow-up time of 1.5 years (range 0–
9 years), 13 patients died and 2 underwent heart trans-
plant. Most of the patients died within the first 2 years of life
(Fig. 4). There was a trend towards a better survival in pa-
tients with HCM (10/14) compared with the DCM group
(10/18) (Table 1). In the HCM group, all the patients who
died suffered from a syndrome or from general myopathy
and three of the four patients who died had an obstructed
left ventricular outflow tract. The group of patients with
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Table 3 Reasons for referral in 35 patients with cardiomyopathy
DCM (N) HCM (N) UCM (N) All (N)
Heart failure 10 7 2 19
Systolic murmur 1 4 0 5
Routine antenatal ultrasound 1 1 0 2
Acute life-threatening event 2 0 1 3
Metabolic disease 1 1 0 2
Family history of cardiomyopathy 2 0 0 2
Genetic syndrome 1 0 0 1
Routine oncological screening 0 1 0 1
Total 18 14 3 35
DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; UCM = unclassified cardiomyopathy.
severe heart failure symptoms within the first month of life
had a significantly worse outcome than the rest of the study
population (p < 0.0001). All the patients who remained
asymptomatic throughout the study period survived. In all
13 patients who died, the cause of death was progressive
heart failure. There was a trend towards a worse outcome in
patients who were diagnosed early: five of eight deaths from
DCM and all four deaths from HCM occurred in patients
who were diagnosed within the neonatal period.
DISCUSSION
This report gives a detailed picture of the aetiology, clinical
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Figure 3 Follow-up of left ventricular size (left ventricular end-diastolic diameter) in survivors (N= 10) and non-survivors (N= 8∗ , dashed line) with dilated cardiomy-
opathy.
∗Patients with a very short follow-up may only have points instead of graphs.
thy in 35 patients diagnosed within the first year of life.
In our study population, the frequency of the various mor-
phologies of cardiomyopathy was similar to that reported
in other series (10,1). DCM was the most common type,
followed by HCM. Restrictive and right ventricular arrhyth-
mogenic cardiomyopathies are rarely diagnosed in infants
(10–12) and were not represented in our cohort.
The incidence of HCM is lower when compared with
older children or adults (10). This may be explained by the
later occurrence of symptoms such as heart failure in HCM
compared to DCM (Table 1). The normal thickness of the
infant ventricular myocardium also shows a much wider
variation range in relation to the size of the heart than in
older patients (6). For this reason, it is possible that the true
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Figure 4 Kaplan–Meier estimates of freedom from death or transplant in 35
patients with cardiomyopathy (95% confidence intervals and numbers at risk).
incidence of HCM in infants is still being underestimated.
The existence of a male predominance of 69–75% in HCM
(10,4) is also supported by our data.
Finding the aetiology of a cardiomyopathy can be time-
consuming and frustrating. The reported success rate is
around 30% (13) and it is 50% in our study. Neverthe-
less, it is important to undertake every effort to establish
the aetiology of the cardiomyopathy because there may be a
causative therapy available. Also, specific screening of other
members of the family and meaningful counselling of the
parents regarding the risk of recurrence is possible only if
the aetiology of the cardiomyopathy is known. It may also
help in forecasting the further course of the disease: in our
study population, the clinical course and the age of death of
patients with known aetiologies were within the previously
published and predicted range for the respective disease in
all patients (Table 2) (14–19).
Recently published guidelines may assist in achieving a
systematic approach in diagnosing cardiomyopathies (8),
and the early involvement of sub-specialists in metabolic,
genetic and neuromuscular diseases is helpful in focussing
these examinations on clinical suspicion and in keeping
costs low. The two leading groups of known aetiologies,
namely genetic syndromes and metabolic diseases (Table 2),
must always be considered when searching for the aetiology
of cardiomyopathy in infants.
In 7 of the 18 patients with unknown aetiologies, my-
ocarditis was suspected but not proved. Neither the patient’s
history nor laboratory testing will help prove or exclude my-
ocardial inflammation, and endomyocardial biopsy is still
the gold standard (13). We in our department are reluctant
to perform an endomyocardial biopsy in infants, because of
its limitations in sensitivity (sampling error) and specificity,
and also the inherent risk of complications.
The prognosis of neonates and infants with symptomatic
cardiomyopathy is poor. Many patients suffer from severe
heart failure and the mortality rate is high (Table 1). Most of
the deaths occur within 2 years after the first presentation
(Fig. 4). Patient selection, however, may have influenced this
bad outcome.
Because of the small number of patients and the retro-
spective study design, we are not able to make further state-
ments about risk factors for death or transplant, but we ob-
served the following trends, which concord with previously
described series (5): mortality was higher in patients with
DCM than in patients with HCM (44 vs. 29%). The severity
of the disease at presentation, as represented by the symp-
toms and the pathologic measurements in echocardiography
scans, also correlated with an adverse outcome. Severe heart
failure at the time of diagnosis results in a higher mortality
rate compared with the group as a whole. In patients with
DCM, the shortening fraction of non-survivors was lower
than that for the survivors (15 vs. 20%). The sex, age at pre-
sentation, ECG and laboratory findings did not influence
the outcome in our population.
The size of the left ventricle in patients with DCM at the
first presentation is not a good predictor for an adverse out-
come: even patients with severely dilated left ventricles are
able to survive, or even normalize their ventricular size and
function (Fig. 3). The reason of the improvement of the left
ventricular size in patients with DCM during the follow-up
cannot be explained by this retrospective study. It does, how-
ever, suggest intermittent rather than chronic or persistent
damage to the myocardium; an inflammation process with
subsequent myocardial recovery and remodelling, as seen
in myocarditis, may be the reason for the DCM in many of
these patients.
The incidence of sudden cardiac death in patients with
diagnosed cardiomyopathy is surprisingly low. It did not
occur in our series and is reported to occur in only 1.3% of all
paediatric patients listed for heart transplant (20). The true
incidence of sudden cardiac death in paediatric patients with
cardiomyopathy is not, however, available. Other studies
reported an incidence of 1% in children with HCM (4) and
11% in children with DCM (21). Sudden death is the first
sign of cardiomyopathy in as many as 3.5% of the patients
(22).
To conclude, cardiomyopathy in infants is a very severe
disease with unspecific symptoms and a highmortality, espe-
cially when presenting in the first month of life. A multidisci-
plinary approach is recommended as there are various rare
aetiologies, which may lead to cardiomyopathy with the two
leading aetiologies being genetic syndromes and metabolic
diseases. History, clinical examination and laboratory test-
ing will be successful in many patients with HCM and in
some patients with DCM.
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